CLINICAL_TRIALS
trial_result
· 2012-03-09
Clinical Trial Update: A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia [Phase 2]
Summary
A Phase 2 trial evaluated silodosin 8 mg daily for nocturia in men with benign prostatic hyperplasia, with results posted after study completion.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Watson Pharmaceuticals | Conditions: Nocturia, Prostatic Hyperplasia | Phase 2 | Status: COMPLETED | Results posted: 2012-03-09